Categories Earnings, Health Care

Obalon Therapeutics (NASDAQ: OBLN): Q3 2019 Earnings Snapshot

— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.

— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier

— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected

— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year

— Research and development expense declined sharply to $1.2 million from $2.4 million last year

—  Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss

— Raised $16.6 million in gross proceeds from an equity offering

— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top